Walden Biosciences Announces Presentation at Canaccord Genuity 42nd Annual Growth Conference
August 04, 2022 07:00 ET
|
Walden Biosciences, Inc.
CAMBRIDGE, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Walden Biosciences, Inc. (Walden), a private, venture-backed biotechnology company focused on transforming the treatment of kidney disease, today...
Unicycive Reports Key Findings from Independent Renal Dietitian Survey
July 26, 2022 07:00 ET
|
Unicycive Therapeutics, Inc.
Hyperphosphatemia ranked as area of greatest unmet need Highlights most appealing benefits of Renazorb as efficacy/potency and lower pill burden Confirms patient preference for pills that are...
Unicycive Reports Key Findings from Market Research with Nephrologists
July 20, 2022 07:12 ET
|
Unicycive Therapeutics, Inc.
Renazorb product profile rated as best-in-class phosphate binder Nephrologists report high prescribing intent for Renazorb pending FDA approval LOS ALTOS, Calif., July 20, 2022 (GLOBE...
OPEN MINDS Community Members, PsychU.org & PKDnetwork.org, Partner To Provide A Webinar Addressing Major Depressive Disorder In Chronic Kidney Disease
December 03, 2019 10:01 ET
|
Open Minds
Gettysburg, Pa, Dec. 03, 2019 (GLOBE NEWSWIRE) -- PsychU.org and PKDnetwork.org have joined forces to provide a cutting edge webinar that will address the mental health challenges of Major...